Par Pharmaceutical Begins Shipment of Generic Glucotrol XL®

WOODCLIFF LAKE, N.J., Sept. 25, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for glipizide 5 mg and 10 mg extended-release (ER) tablets.  Glipizide ER is the generic version of Pfizer's Glucotrol XL^® and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.    

Par has begun shipping 5 mg and 10 mg strengths of the product.  According to IMS Health data, annual U.S. sales of the 5 mg and 10 mg strengths of glipizide ER are approximately $89 million. 

Important Information About Glipizide ER Tablets
Glipizide extended-release tablets are contraindicated in patients with: a known hypersensitivity to glipizide or any excipients in the tablets; and Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma.  This condition should be treated with insulin.

About Par Pharmaceutical Companies, Inc. 
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.  For press release and other company information, visit www.parpharm.com. 

SOURCE Par Pharmaceutical Companies, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED